FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval
Article Related Press Releases (1) Related Articles (4) Related SEC Filings (1) Stock Quotes (1) Comments (0)
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Below is the FDA's approval letter Heron Therapeutics' (Nasdaq: HRTX) SUSTOL:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review
- LinkedIn (LNKD), Microsoft (MSFT) Deal Closes
- Insys Therapeutics (INSY) Sinks as Former Employees Arrested in Racketeering Scheme
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!